Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts on the central nervous system to relieve pain. It is prescribed for: - Chronic musculoskeletal pain: provides long‑lasting relief for conditions such as osteoarthritis and low‑back pain. - Neuropathic pain associated with diabetic peripheral neuropathy: reduces pain intensity in affected nerves. - Cancer‑related chronic pain: helps manage persistent pain in oncologic patients when other opioids are insufficient.

Tapentadol Hydrochloride may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: sensation of light‑headedness or unsteadiness. - Constipation: reduced bowel movements, often requiring dietary management. - Headache: mild to moderate pain in the head region. - Somnolence: increased sleepiness or fatigue. - Dry mouth: reduced salivation causing a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Seizures: convulsive episodes, particularly in patients with a seizure history. - Severe hypotension: marked drop in blood pressure leading to fainting. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of developing opioid use disorder. - adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing Tapetadol Hydrochloride, clinicians should consider several safety measures.

- Assess pain severity and prior opioid exposure: ensure suitability for opioid therapy. - Evaluate renal and hepatic function: dose adjustments may be required in impairment. - Monitor for signs of respiratory depression: especially during dose initiation or escalation. - Avoid concomitant CNS depressants: reduces additive sedation risk. - Counsel patients on constipation management: recommend diet, fluids, and laxatives. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture.

Tapentadol Hydrochloride can interact with several medication classes, requiring careful review.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation and respiratory depression. - MAO inhibitors: increase risk of hypertensive crisis and serotonin syndrome.\n- Strong CYP2D6 inhibitors (CYP ​  ):  

Moderate Interactions (Monitor Closely): - Serotonergic agents (SSRIs, SNRIs): may potentiate serotonin syndrome. - Antihistamines and anti‑emetics: additive sedation effects. - Diuretics: may enhance hypotensive response. - Anticonvulsants: potential alteration of seizure threshold. - Alcohol: increases central nervous system depression.